drugset
drugset / Trial / NCT04840758

Stereotactic Ablation Radiotherapy Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer

NCT04840758 ↗

Phase 1/2 Unknown 39 enrolled The First Affiliated Hospital of Xiamen University
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess of the Safety and Effects of Stereotactic Ablation Radiotherapy (SABR) combined with Sintilimab in early inoperable synchronous Multiple Primary Lung Cancer (sMPLC)

Timeline

Start
2021-06
Primary completion
2022-12
Completion
2023-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Sintilimab Monoclonal antibody 200 mg Intravenous

Indications

lung cancer